Oncolytics surges on Fast Track status for pelareorep in colorectal cancer
Source: SeekingAlpha
2026-02-04 09:51:06 ET
More on Oncolytics Biotech
- Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
- Oncolytics rises on additional data for pelareorep in colorectal cancer
- Oncolytics, FDA agree on phase 3 trial design for Pelareorep in pancreatic cancer
- Seeking Alpha’s Quant Rating on Oncolytics Biotech
- Historical earnings data for Oncolytics Biotech
Read the full article on Seeking Alpha
For further details see:
Oncolytics surges on Fast Track status for pelareorep in colorectal cancer
Oncolytics Biotech Inc.
NASDAQ: ONCY
ONCY Trading
6.76% G/L:
$1.105 Last:
5,276,502 Volume:
$1.14 Open:
ONCY Latest News
June 01, 2026 09:00:00 am
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
May 26, 2026 09:00:00 am
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
ONCY Stock Data
$91,131,840
106,702,482
13.96%
27
N/A
Biotechnology & Life Sciences
Healthcare
CA
San Diego
